Konrad van der Zwet

Konrad van der Zwet

Auto-generated profile, based on publicly available information

Konrad van der Zwet

Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2023 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
ADAnouk A.M.T. Donners
Anouk A.M.T. Donners
KZKonrad van der Zwet
Konrad van der Zwet
CRCarin M.A. Rademaker
Carin M.A. Rademaker
TEToine C.G. Egberts
Toine C.G. Egberts
RSRoger E.G. Schutgens
Roger E.G. Schutgens
KFKathelijn Fischer
Kathelijn Fischer
Prophylaxis with emicizumab provides effective bleeding protection in persons with hemophilia A (PwHA) but pressures healthcare budgets. The body weight-adjusted dosing at 7-, 14-, or 28-day intervals, according to the label, often mismatches the vial content. Entire-vial dosing resulted in therapeutic concentrations according to pharmacokinetic simulations and was introduced to avoid waste. The objective of this study was to evaluate the efficacy of entire-vial dosing of emicizumab by investigating real-world evidence of plasma concentrations, bleeds, and drug waste. This is a single-center, observational study with PwHA receiving emicizumab in mg/kg doses according to label but dosing interval extrapolated to the nearest vial size. Patient characteristics and bleeds were compared 1 year before starting emicizumab and during emicizumab until January 2022. Concentrations were assessed at weeks 4, 12, and annually. The mean (95% CI) annualized bleed rates were compared by using negative binomial regression. Drug waste between label-based dosing and entire-vial dosing was compared. A total of 112 individuals (94% severe phenotype and 9% positive FVIII inhibitors) were followed for a median of 56 weeks (interquartile range [IQR] 52-68) before and 51 weeks (IQR 29-75) after starting emicizumab. The median emicizumab dose was 5.9 (IQR 5.5-6.2) mg/kg/4 wk with median concentrations of 63 (IQR 51-80) μg/mL. The annualized bleed rate of treated bleeds before emicizumab was 3.6 (95% CI 2.9-4.4) and was 0.8 (95% CI 0.6-1.1) during emicizumab (P < .001). Drug waste was reduced by 9%. The entire-vial dosing of emicizumab is an attractive treatment option for PwHA leading to therapeutic plasma concentrations, good bleeding control, and drug waste avoidance.

5 April 2024 in Haemophilia
Verified
Journal Article
Open access
KZKonrad van der Zwet
Konrad van der Zwet
MKMarloes de Kovel
Marloes de Kovel
JMJayashree Motwani
Jayashree Motwani
CGChris van Geet
Chris van Geet
BNBeatrice Nolan
Beatrice Nolan
TIthe PedNet Investigators
the PedNet Investigators
Introduction: Despite the rapid uptake of emicizumab in the paediatric haemophilia A (HA) population, real‐world data on the safety and efficacy is limited.Aim: To report on bleeding and safety in paediatric patients receiving emicizumab prophylaxis.Methods: Data were extracted from the multicentre prospective observational PedNet Registry (NCT02979119). Children with haemophilia A, and ≥50 FVIII exposures or inhibitors present receiving emicizumab maintenance therapy were analysed. Data were summarized as medians with interquartile range (IQR, P25–P75). Mean (95% confidence interval (CI)), annualized (joint) bleeding rate (A(J)BR) during emicizumab and ≤2 years before emicizumab prophylaxis were modelled and compared using negative binomial regression.Results: Total of 177 patients started emicizumab at median 8.6 years (IQR 4.8–13.1), most had no FVIII inhibitors (64%). Follow up before emicizumab was median: 1.68 years (IQR: 1.24–1.90) and during emicizumab: 1.32 years (IQR: .94–2.11).In patients without inhibitors, mean ABR reduced after starting emicizumab from 2.41 (CI 1.98–2.95) to 1.11 (CI .90–1.36, p < .001), while AJBR reduced from.74 (CI .56–.98) to.31 (CI .21–.46, p < .001). Concordantly, in patients with inhibitors, mean ABR reduced from 5.08 (CI 4.08–6.38) to .75 (CI .56–1.01, p < .001), while AJBR reduced from 1.90 (CI 1.42–2.58) to .34 (CI .21–.56, p < .001). Five emicizumab‐related adverse events were reported (3% of the cohort), including one patient with antidrug antibodies.Conclusion: This study showed improved bleeding control compared to previous treatment and a favourable safety profile during emicizumab therapy in paediatric haemophilia A patients.

8 November 2025 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
KZKonrad van der Zwet
Konrad van der Zwet
AVAmber D.W. de Vos
Amber D.W. de Vos
MCMarjon H. Cnossen
Marjon H. Cnossen
FHFloor C.J.I. Heubel-Moenen
Floor C.J.I. Heubel-Moenen
SSSaskia Schols
Saskia Schols
DKDavid Keeling
David Keeling
Emicizumab provides effective prophylaxis in hemophilia A (HA), but its cost puts a burden on healthcare systems. Pharmacokinetic-pharmacodynamic analyses suggest that emicizumab is effective at lower trough concentrations (Ctrough) than the mean 55 μg/ml reported on conventional dosing. Interim analysis comparing bleeding control during 6 months' of conventional emicizumab dosing versus pharmacokinetic (PK) guided dosing in participants with HA, targeting a Ctrough of 30 ± 5 μg/ml. The DosEmi study (NCT06320626) is an ongoing multicenter, open-label, crossover, Dutch trial. Eligible were participants ≥ 16 years using emicizumab for ≥12 months with good bleeding control (≤2 treated bleeds/6 months, none spontaneous). This planned interim analysis compared 6 months' bleeding on conventional dosing versus PK-guided dosing. Study continuation criteria were ≤15% decrease in the proportion without treated bleeds, maximum 2 spontaneous bleeds overall observed, and <1.0 increase in bleeds/year (ABR). In 26 participants with severe HA PK-guided dosing reduced emicizumab consumption by 39% (range 13-50%). The proportion of participants without treated bleeds was 69% during conventional versus 58% during PK-guided dosing (risk difference +11%, p= 0.254); while the proportion without joint bleeds remained stable 85% vs 88% respectively (risk difference -4%, p=0.500). ABR remained low (0.7 versus 0.9, p=0.132), including one spontaneous muscle bleed (emicizumab concentration 52.5 μg/ml). These interim-results suggest that bleeding control on PK-guided reduced dosing of emicizumab (target Ctrough 30±5 μg/mL) is similar to conventional dosing. All pre-specified criteria for study continuation and inclusion of participants <16 years were met.

3 April 2024 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
KZKonrad van der Zwet
Konrad van der Zwet
KGKarin P.M. van Galen
Karin P.M. van Galen
AEAnnemiek C.C. Evers
Annemiek C.C. Evers
KFKathelijn Fischer
Kathelijn Fischer
RSRoger E.G. Schutgens
Roger E.G. Schutgens
LVLize van Vulpen
Lize van Vulpen
Von Willebrand disease (VWD) type 3 is characterized by a complete deficiency of von Willebrand factor (VWF), resulting in a severe bleeding phenotype. Treatment often requires administration of VWF concentrates/factor (F)VIII. However, the development of alloantibodies is a rare complication, resulting in ineffective recovery and allergic reactions. Emicizumab, a bispecific antibody mimicking FVIII function, has emerged as a potential alternative, with promising results reported in several case reports. Description of multiple approaches to control highly severe postpartum hemorrhage in type 3 VWD with alloantibodies, including off-label use of emicizumab. Here we present a 28-year-old patient with type 3 VWD and alloantibodies, known to have arthropathy of the right elbow. Previous immune tolerance induction was unsuccessful. Despite receiving negative pregnancy advice during preconception counseling, the patient became pregnant. Delivery was induced at 38 4/7 weeks with prostaglandin, and recombinant FVIIa (rFVIIa) was administered every 2 hours. Despite administration of rFVIIa, bleeding persisted, requiring manual placental removal and insertion of a Bakri balloon. Since bleeding persisted, plasma-derived VWF was administered with an initial excellent recovery and successful embolization of the uterine artery. Twelve days postpartum, she developed endometritis and recurrent vaginal bleeding treated with antibiotics, rFVIIa every 2 hours, and multiple erythrocyte transfusions. Plasma-derived VWF was administered but was complicated by anaphylaxis and no recovery. Due to persistent vaginal bleeding, reembolization of uterine arteries was performed and off-label emicizumab was initiated. Twenty-nine days postpartum, she developed septic shock requiring an abdominal hysterectomy, again complicated by severe bleeding necessitating direct intraabdominal packing after rFVIIa. A computed tomography scan 9 days postsurgery revealed thrombosis in the left iliac vein and asymptomatic pulmonary embolisms. rFVIIa was stopped and prophylactic low-molecular-weight heparin was started. The patient was discharged 2 months after delivery on low-dose low-molecular-weight heparin, emicizumab, and antibiotics for an intra-abdominal abscess. During 2.5 years of emicizumab prophylaxis, she has had no rebleeding in her arthropathic right elbow. The current case emphasizes the postpartum clinical challenges of patients with type 3 VWD and alloantibodies. It underscores the potential role of emicizumab in maintaining hemostatic control.

17 December 2024 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
KZKonrad van der Zwet
Konrad van der Zwet
MRMark Roest
Mark Roest
DHDana Huskens
Dana Huskens
RSRoger E.G. Schutgens
Roger E.G. Schutgens
LVLize van Vulpen
Lize van Vulpen
RURolf T. Urbanus
Rolf T. Urbanus
Emicizumab, a bispecific antibody that mimics factor (F)VIII, has significantly improved hemophilia A management. Although emicizumab levels can be measured, tools for estimating the hemostatic efficacy of emicizumab are lacking. Thrombin generation (TG) assays can distinguish bleeding phenotypes in persons with hemophilia A on FVIII prophylaxis and may also be used during emicizumab therapy. To assess the association between TG parameters, emicizumab levels, and bleeding in patients on emicizumab therapy. A single-center longitudinal cohort study was conducted, with samples collected during the steady-state phase of emicizumab therapy. TG was measured using tissue factor (TF; TF-TG, 1 pM) and FXIa (FXIa-TG, 200 pM). Emicizumab concentrations were determined with mass spectrometry. Only treated bleeds were recorded. Pearson correlations (rho, r) were reported. Eighty-five samples from 49 patients were analyzed during a median of 1 year of emicizumab therapy. Most bleeds were traumatic (97%; n = 30), whereas 1 bleed was spontaneous. At 12 months, TF-TG (r = 0.42) showed a borderline correlation, and FXIa-TG (r = 0.15) showed no correlation with emicizumab concentrations. Although FXIa-TG showed a 9% higher endogenous thrombin potential in patients with zero vs ≥1 treated bleed (endogenous thrombin potential: 957 vs 878 nM/min, P = .045), neither the FXIa-peak height nor TF-TG showed any association with traumatic bleeding. TG parameters showed no clinically relevant correlations with emicizumab plasma concentrations, were not associated with traumatic bleeding, and showed considerable intrapatient variability. Therefore, TG was not considered useful for monitoring coagulation potential in patients on steady-state emicizumab prophylaxis.